$ITOS
iTeos Therapeutics, Inc.

2022 Q1 Form 10-Q Financial Statement

#000095017022009668 Filed on May 12, 2022

View on sec.gov

Income Statement

Concept 2022 Q1 2021 Q1
Revenue $152.5M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $10.62M $7.050M
YoY Change 50.57% 191.32%
% of Gross Profit
Research & Development $21.10M $11.64M
YoY Change 81.19% 99.88%
% of Gross Profit
Depreciation & Amortization $180.0K $130.0K
YoY Change 38.46% 8.33%
% of Gross Profit
Operating Expenses $31.71M $18.69M
YoY Change 69.68% 126.73%
Operating Profit $120.8M -$18.69M
YoY Change -746.43% 126.73%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$2.023M $240.0K
YoY Change -942.92% -671.43%
Pretax Income $119.5M -$13.53M
YoY Change -983.21% 157.79%
Income Tax $49.95M
% Of Pretax Income 41.79%
Net Earnings $69.58M -$13.53M
YoY Change -614.13% 157.94%
Net Earnings / Revenue 45.62%
Basic Earnings Per Share $1.96 -$0.39
Diluted Earnings Per Share $1.82 -$0.39
COMMON SHARES
Basic Shares Outstanding 35.49M 35.09M
Diluted Shares Outstanding 38.14M 35.09M

Balance Sheet

Concept 2022 Q1 2021 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $824.0M $321.4M
YoY Change 156.37% 117.6%
Cash & Equivalents $824.0M $321.5M
Short-Term Investments
Other Short-Term Assets $12.06M $2.300M
YoY Change 424.22% 76.92%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $840.7M $324.9M
YoY Change 158.74% 117.62%
LONG-TERM ASSETS
Property, Plant & Equipment $2.216M $4.400M
YoY Change -49.64% 266.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $316.0K $400.0K
YoY Change -21.0% 0.0%
Total Long-Term Assets $9.661M $8.000M
YoY Change 20.76% 70.21%
TOTAL ASSETS
Total Short-Term Assets $840.7M $324.9M
Total Long-Term Assets $9.661M $8.000M
Total Assets $850.3M $332.9M
YoY Change 155.43% 116.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $10.60M $5.300M
YoY Change 100.06% 17.78%
Accrued Expenses $14.05M $5.314M
YoY Change 164.43% 66.06%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $174.3M $11.80M
YoY Change 1376.72% 18.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $30.00K $8.500M
YoY Change -99.65% 88.89%
Total Long-Term Liabilities $30.00K $8.500M
YoY Change -99.65% 88.89%
TOTAL LIABILITIES
Total Short-Term Liabilities $174.3M $11.80M
Total Long-Term Liabilities $30.00K $8.500M
Total Liabilities $223.9M $20.30M
YoY Change 1003.17% 40.0%
SHAREHOLDERS EQUITY
Retained Earnings $210.2M
YoY Change
Common Stock $36.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $626.4M $312.6M
YoY Change
Total Liabilities & Shareholders Equity $850.3M $332.9M
YoY Change 155.43% 116.17%

Cashflow Statement

Concept 2022 Q1 2021 Q1
OPERATING ACTIVITIES
Net Income $69.58M -$13.53M
YoY Change -614.13% 157.94%
Depreciation, Depletion And Amortization $180.0K $130.0K
YoY Change 38.46% 8.33%
Cash From Operating Activities -$24.00M -$14.79M
YoY Change 62.29% -2938.77%
INVESTING ACTIVITIES
Capital Expenditures $227.0K $88.00K
YoY Change 157.95% 225.93%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$323.0K -$91.00K
YoY Change 254.95% 145.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $333.0K $667.0K
YoY Change -50.07%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 333.0K 667.0K
YoY Change -50.07% -99.48%
NET CHANGE
Cash From Operating Activities -24.00M -14.79M
Cash From Investing Activities -323.0K -91.00K
Cash From Financing Activities 333.0K 667.0K
Net Change In Cash -24.56M -14.93M
YoY Change 64.46% -111.68%
FREE CASH FLOW
Cash From Operating Activities -$24.00M -$14.79M
Capital Expenditures $227.0K $88.00K
Free Cash Flow -$24.23M -$14.88M
YoY Change 62.85% -3111.74%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2022Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2022Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2022Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2022Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2022Q1 dei Entity Shell Company
EntityShellCompany
false
CY2022Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35540704
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
823984000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
848537000
CY2022Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4619000
CY2021Q4 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
CY2022Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001808865
CY2022Q1 dei Amendment Flag
AmendmentFlag
false
CY2022Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2022Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2022Q1 dei Document Type
DocumentType
10-Q
CY2022Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2022Q1 dei Document Period End Date
DocumentPeriodEndDate
2022-03-31
CY2022Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2022Q1 dei Entity File Number
EntityFileNumber
001-39401
CY2022Q1 dei Entity Registrant Name
EntityRegistrantName
iTeos Therapeutics, Inc.
CY2022Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2022Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-3365066
CY2022Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
321 Arsenal St
CY2022Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Watertown
CY2022Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2022Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02472
CY2022Q1 dei City Area Code
CityAreaCode
339
CY2022Q1 dei Local Phone Number
LocalPhoneNumber
217 0161
CY2022Q1 dei Security12b Title
Security12bTitle
Common stock, $0.001 par value per share
CY2022Q1 dei Trading Symbol
TradingSymbol
ITOS
CY2022Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2022Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2022Q1 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
0
CY2021Q4 itos Research And Development Tax Credit Receivable Current
ResearchAndDevelopmentTaxCreditReceivableCurrent
524000
CY2022Q1 us-gaap Income Tax Receivable
IncomeTaxReceivable
0
CY2021Q4 us-gaap Income Tax Receivable
IncomeTaxReceivable
7544000
CY2022Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
12057000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
14086000
CY2022Q1 us-gaap Assets Current
AssetsCurrent
840660000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
874713000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2216000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q1 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
1599000
CY2021Q4 itos Research And Development Tax Credit Receivable Non Current
ResearchAndDevelopmentTaxCreditReceivableNonCurrent
2004000
CY2022Q1 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
296000
CY2021Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
298000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5234000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
5329000
CY2022Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
316000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
296000
CY2022Q1 us-gaap Assets
Assets
850321000
CY2021Q4 us-gaap Assets
Assets
884712000
CY2022Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
10603000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
5145000
CY2022Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
14052000
CY2021Q4 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
17157000
CY2022Q1 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
20107000
CY2022Q1 us-gaap Deferred Income Current
DeferredIncomeCurrent
1002000
CY2021Q4 us-gaap Deferred Income Current
DeferredIncomeCurrent
827000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
127703000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
280225000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
786000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
770000
CY2022Q1 us-gaap Liabilities Current
LiabilitiesCurrent
174253000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
304124000
CY2022Q1 itos Grants Repayable
GrantsRepayable
5899000
CY2021Q4 itos Grants Repayable
GrantsRepayable
6164000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4461000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4571000
CY2022Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
39300000
CY2021Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
17000000
CY2022Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
30000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
33000
CY2022Q1 us-gaap Liabilities
Liabilities
223943000
CY2021Q4 us-gaap Liabilities
Liabilities
331892000
CY2022Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2022Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35516912
CY2022Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35516912
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
35466001
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
35466001
CY2022Q1 us-gaap Common Stock Value
CommonStockValue
36000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
35000
CY2022Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
417705000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
413180000
CY2022Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1568000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-1018000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
210205000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
140623000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
626378000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
850321000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
884712000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
152522000
CY2022Q1 us-gaap Revenues
Revenues
152522000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
21096000
CY2021Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11643000
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10615000
CY2021Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
7046000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
31711000
CY2021Q1 us-gaap Operating Expenses
OperatingExpenses
18689000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
120811000
CY2021Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-18689000
CY2022Q1 itos Grant Income
GrantIncome
491000
CY2021Q1 itos Grant Income
GrantIncome
4915000
CY2022Q1 itos Research And Development Tax Credits
ResearchAndDevelopmentTaxCredits
254000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2023000
CY2021Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
240000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
119533000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13534000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49951000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69582000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.96
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.82
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35493272
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35086662
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38135957
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35086662
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69582000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-550000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-24002000
CY2021Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-14790000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
227000
CY2021Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
88000
CY2022Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
96000
CY2021Q1 us-gaap Payments To Acquire Other Productive Assets
PaymentsToAcquireOtherProductiveAssets
3000
CY2022Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
194000
CY2021Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-3740000
CY2022Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-152522000
CY2022Q1 itos Increase Decrease In Uncertain Tax Benefit
IncreaseDecreaseInUncertainTaxBenefit
22300000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-323000
CY2021Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-305000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
69032000
CY2021Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-13839000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
323197000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2584000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
667000
CY2021Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-305000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-13534000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
312609000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
552820000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4193000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
333000
CY2022Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-550000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69582000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
626378000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
69582000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-13534000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
180000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
126000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
4193000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
2584000
CY2022Q1 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
2000
CY2021Q1 itos Change In Operating Lease Right Of Use Assets
ChangeInOperatingLeaseRightOfUseAssets
6000
CY2022Q1 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-684000
CY2021Q1 itos Increase Decrease In Grants Receivable
IncreaseDecreaseInGrantsReceivable
-1149000
CY2022Q1 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-889000
CY2021Q1 itos Increase Decrease In Research And Development Tax Credit Receivable
IncreaseDecreaseInResearchAndDevelopmentTaxCreditReceivable
-191000
CY2022Q1 itos Refundable Income Taxes
RefundableIncomeTaxes
7544000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1810000
CY2021Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-493000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
5465000
CY2021Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2348000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3062000
CY2021Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2115000
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
20107000
CY2021Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-91000
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
333000
CY2021Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
667000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
333000
CY2021Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
667000
CY2022Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-563000
CY2021Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-717000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24555000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-14931000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
848835000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
336454000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
824280000
CY2021Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
321523000
CY2022Q1 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
184000
CY2021Q1 itos Capital Expenditure Included In Accounts Payable
CapitalExpenditureIncludedInAccountsPayable
0
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
199000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3206000
CY2022Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021Q1 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
CY2021 us-gaap Net Income Loss
NetIncomeLoss
214500000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
69600000
CY2022Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
210200000
CY2022Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
792477000
CY2022Q1 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
792477000
CY2021Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
797448000
CY2021Q4 us-gaap Financial Instruments Owned At Fair Value
FinancialInstrumentsOwnedAtFairValue
797448000
CY2022Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5288000
CY2021Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
5043000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
3072000
CY2021Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2971000
CY2022Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2216000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
2072000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
200000
CY2021Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
100000
CY2022Q1 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
11041000
CY2021Q4 itos Accrued Clinical Trial Costs Current
AccruedClinicalTrialCostsCurrent
12991000
CY2022Q1 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
2692000
CY2021Q4 itos Accrued Personnel Costs Current
AccruedPersonnelCostsCurrent
3884000
CY2022Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
57000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
25000
CY2022Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
262000
CY2021Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2022Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
14052000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
17157000
CY2022Q1 itos Upfront Payment Received
UpfrontPaymentReceived
625000000.0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5207084
CY2022Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4193000
CY2021Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2584000
CY2021Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
280225000
CY2022Q1 itos Contract With Customer Liability Deductions
ContractWithCustomerLiabilityDeductions
-152522000
CY2022Q1 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
127703000
CY2022Q1 us-gaap Research And Development Arrangement With Federal Government Costs Incurred Net
ResearchAndDevelopmentArrangementWithFederalGovernmentCostsIncurredNet
1500000
CY2022Q1 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.30
CY2021 itos Percentage Of Royalty On Revenue
PercentageOfRoyaltyOnRevenue
0.0012
CY2022Q1 itos Grant Income
GrantIncome
491000
CY2021Q1 itos Grant Income
GrantIncome
4915000
CY2022Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4619000
CY2021Q1 us-gaap Grants Receivable Current
GrantsReceivableCurrent
4022000
CY2022Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6042000
CY2021Q1 us-gaap Deferred Income Noncurrent
DeferredIncomeNoncurrent
6164000
CY2020Q3 us-gaap Common Stock Voting Rights
CommonStockVotingRights
Each share of common stock entitles the holders to one vote on all matters submitted to a vote of the Company’s stockholders.
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage
SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
0.25
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P36M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
14.35
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y8M12D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
758125
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
36.62
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
16763
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.44
CY2022Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
50911
CY2022Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.53
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5897535
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
17.31
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y9M18D
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
96057
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
2332775
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
10.10
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y3M18D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
52695
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
26.54
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
31.98
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0137
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0196
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0042
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0071
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.86
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.91
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.99
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
1
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-14886000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-7054000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
134419000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
-6480000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
119533000
CY2021Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-13534000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
49951000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.418
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.418
CY2021Q1 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Tax Credits Foreign
EffectiveIncomeTaxRateReconciliationTaxCreditsForeign
0.25
CY2022Q1 us-gaap Liability For Uncertain Tax Positions Current
LiabilityForUncertainTaxPositionsCurrent
22300000
CY2022Q1 us-gaap Land Subject To Ground Leases
LandSubjectToGroundLeases
1577
CY2022Q1 us-gaap Other Commitments Description
OtherCommitmentsDescription
In January 2021, the Company entered into an amendment to extend the lease, effective February 2021 with a termination date of January 2030, and increase the office and laboratory space
CY2022Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
300000
CY2021Q1 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
200000
CY2022Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y8M12D
CY2021Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P5Y10M24D
CY2022Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0477
CY2021Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0476
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
199000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3206000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
250000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
179000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
824000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
1037000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
1018000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
985000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
954000
CY2022Q1 itos Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
1274000
CY2022Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
6092000
CY2022Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
845000
CY2022Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
5247000
CY2022Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
786000
CY2022Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
4461000
CY2022Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
69582000
CY2021Q1 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13534000
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35493272
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
35086662
CY2022Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
2642685
CY2021Q1 us-gaap Incremental Common Shares Attributable To Share Based Payment Arrangements
IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
0
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
38135957
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
35086662
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
1.96
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
1.82
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39

Files In Submission

Name View Source Status
0000950170-22-009668-index-headers.html Edgar Link pending
0000950170-22-009668-index.html Edgar Link pending
0000950170-22-009668.txt Edgar Link pending
0000950170-22-009668-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
itos-20220331.htm Edgar Link pending
itos-20220331.xsd Edgar Link pending
itos-20220331_cal.xml Edgar Link unprocessable
itos-20220331_def.xml Edgar Link unprocessable
itos-20220331_htm.xml Edgar Link completed
itos-20220331_lab.xml Edgar Link unprocessable
itos-20220331_pre.xml Edgar Link unprocessable
itos-ex31_1.htm Edgar Link pending
itos-ex31_2.htm Edgar Link pending
itos-ex32_1.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending